Introduction / overview of successes: Alastair Greystoke (Newcaslte University, UK)

Regulatory perspective: Elias Pean (EMA, NL)

Moving from experimental phase to evidence-based practice, a payer’s perspective: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (CZ, NL) – the speaker didn’t give the consent to share the presentation

Scene-setting (in a forward looking way): Sid Mathur (MSD, US)

Industry perspective: Lynn Brown (MSD, US)

Regulatory perspective: Hilke Zander (Paul-Elrich Institut, DE)

Evolution of comprehensive genomic profiling in precision medicine: David Fabrizio (Foundation Medicine, US)

Biomarker harmonisation: TMB case study: Jeff Allen (Friends of Cancer Research, US)

Regulatory perspective: Dr Theodor Framke (EMA, NL)

Academic perspective: Prof Lucinda Billingham (University of Birmingham, UK)

Early phase side of drug development – Industry perspective: Richardus Vonk – the speaker didn’t give his consent to share the presentation

Why equality and quality matters: Olga Valcina (OncoAlliance, LV, Deputy Director on Laboratory Matters, Institute of Food Safety, Animal Health and Environment “BIOR”)

Genomic standards: Prof Eivind Hovig (University of Oslo, NO)

Distributed data governance – Addressing the precision public health dilemma: Philippe Page (The Human Colossus, CH)